Home Type 2 Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis | BMC Medicine

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis | BMC Medicine

by Yu An
0 comment
  • Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet (London, England). 2022;400(10365):1803–20.

    Article 
    PubMed 

    Google Scholar
     

  • IDF diabetes Atlas. 9th edn. Brussels, Belgium: International Diabetes Federation: International Diabetes Federation; 2019 Available from: https://www.diabetesatlas.org.

  • Tinajero MG, Malik VS. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021;50(3):337–55.

    Article 
    PubMed 

    Google Scholar
     

  • Ogurtsova K, Guariguata L, Barengo NC, Ruiz PL-D, Sacre JW, Karuranga S, et al. IDF diabetes Atlas Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Res Clin Pract. 2022;183:109118.

    Article 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801.

    Article 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology (Baltimore, MD). 2016;64(1):73–84.

    Article 
    PubMed 

    Google Scholar
     

  • Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology (Baltimore, MD). 2016;64(1):19–22.

    Article 
    PubMed 

    Google Scholar
     

  • Tanase DM, Gosav EM, Costea CF, Ciocoiu M, Lacatusu CM, Maranduca MA, et al. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD). J Diabetes Res. 2020;2020:3920196.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599–612.

    Article 
    PubMed 

    Google Scholar
     

  • Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284–96.

    Article 
    PubMed 

    Google Scholar
     

  • Younossi ZM. Non-alcoholic fatty liver disease – A global public health perspective. J Hepatol. 2019;70(3):531–44.

    Article 
    PubMed 

    Google Scholar
     

  • Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology (Baltimore, MD). 2012;56(3):943–51.

    Article 
    PubMed 

    Google Scholar
     

  • Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617–49.

    Article 
    PubMed 

    Google Scholar
     

  • Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018;41(2):372–82.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Morrison AE, Zaccardi F, Khunti K, Davies MJ. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis. Liver Int. 2019;39(3):557–67.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–44.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mantovani A, Petracca G, Beatrice G, Tilg H, Byrne CD, Targher G. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. Gut. 2021;70(5):962–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–9.

    Article 
    PubMed 

    Google Scholar
     

  • Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75(2):454–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Moher D, Liberati A, Tetzlaff J, Altman DG, Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals Int Med. 2009;151(4):264–9.

    Article 

    Google Scholar
     

  • Sutton AJ, Song F, Gilbody SM, Abrams KR. Modelling publication bias in meta-analysis: a review. Stat Methods Med Res. 2000;9(5):421–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article 
    PubMed 

    Google Scholar
     

  • Hu J, Dong Y, Chen X, Liu Y, Ma D, Liu X, et al. Prevalence of suicide attempts among Chinese adolescents: A meta-analysis of cross-sectional studies. Compr Psychiatry. 2015;61:78–89.

    Article 
    PubMed 

    Google Scholar
     

  • Higgins J, Green SR. Cochrane Handbook for Systematic Review of Interventions. 2011. Version 5.1.0. http://handbook-5-1.cochrane.org.

  • Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6.

    Article 
    PubMed 

    Google Scholar
     

  • Shimada M, Hashimoto E, Kaneda H, Noguchi S, Hayashi N. Nonalcoholic steatohepatitis: risk factors for liver fibrosis. Hepatol Res. 2002;24(4):429–38.

    Article 
    PubMed 

    Google Scholar
     

  • Shi YW, Wang QY, Zhao XY, Sun YM, Kong YY, Ou XJ, et al. Non-obese patients with nonalcoholic fatty liver disease may use a lower liver stiffness cut-off to assess fibrosis stages. J Dig Dis. 2020;21(5):279–86.

    Article 
    PubMed 

    Google Scholar
     

  • Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG. Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol. 2003;17(1):38–42.

    Article 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clinical Gastroenterol Hepatol. 2004;2(3):262–5.

    Article 

    Google Scholar
     

  • Han E, Kim MK, Im SS, Jang BK, Kim HS. Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity. J Diabetes Complications. 2022;36(8):108253.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bahcecioglu IH, Koruk M, Yilmaz O, Bolukbas C, Bolukbas F, Tuncer I, et al. Demographic and clinicopathological characteristics of nonalcoholic fatty liver disease in the East-Southeastern Anatolia regions in Turkey. Med Princ Pract. 2006;15(1):62–8.

    Article 
    PubMed 

    Google Scholar
     

  • Nonomura A, Enomoto Y, Takeda M, Tamura T, Kasai T, Yoshikawa T, et al. Clinical and pathological features of non-alcoholic steatohepatitis. Hepatol Res. 2005;33(2):116–21.

    Article 
    PubMed 

    Google Scholar
     

  • Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15(3):310–5.

    Article 
    PubMed 

    Google Scholar
     

  • Singh H, Pollock R, Uhanova J, Kryger M, Hawkins K, Minuk GY. Symptoms of obstructive sleep apnea in patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2005;50(12):2338–43.

    Article 
    PubMed 

    Google Scholar
     

  • VoPham T, Kim NJ, Berry K, Mendoza JA, Kaufman JD, Ioannou GN. PM(2.5) air pollution exposure and nonalcoholic fatty liver disease in the Nationwide Inpatient Sample. Environ Res. 2022;213:113611.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Thomas CE, Yu YC, Luu HN, Wang R, Paragomi P, Behari J, et al. Neutrophil-lymphocyte ratio in relation to risk of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Cancer Med. 2023;12(3):3589–600.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lima ML, Mourão SC, Diniz MT, Leite VH. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15(5):661–9.

    Article 
    PubMed 

    Google Scholar
     

  • Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM, et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology (Baltimore, MD). 2005;41(2):372–9.

    Article 
    PubMed 

    Google Scholar
     

  • Arun J, Clements RH, Lazenby AJ, Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg. 2006;16(10):1351–8.

    Article 
    PubMed 

    Google Scholar
     

  • Wong VW, Hui AY, Tsang SW, Chan JL, Tse AM, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2006;4(9):1154–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wong VW, Hui AY, Tsang SW, Chan JL, Wong GL, Chan AW, et al. Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;24(8):1215–22.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Riley TR 3rd, Kahn A. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Dig Dis Sci. 2006;51(1):41–4.

    Article 
    PubMed 

    Google Scholar
     

  • Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22(7):1086–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Khurram M, Ashraf MM. A clinical and biochemical profile of biopsy-proven non-alcoholic Fatty liver disease subjects. J Coll Physicians Surg Pak JCPSP. 2007;17(9):531–4.

    PubMed 

    Google Scholar
     

  • Zhang L, Pu K, Chai Z, Dixon JB. Family history of coronary heart disease is associated with a higher incidence of nonalcoholic fatty liver disease Central obesity the likely link. Obes Res Clin Pract. 2007;1(2):I–ii.

    Article 
    PubMed 

    Google Scholar
     

  • Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57(10):1441–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • De Lusong MA, Labio E, Daez L, Gloria V. Non-alcoholic fatty liver disease in the Philippines: comparable with other nations? World J Gastroenterol. 2008;14(6):913–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9 (1229.e1221-1222).

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bjørnå ER, Engelsen MT, El-Serag HB, Ness-Jensen E. Prevalence and risk factors of nonalcoholic fatty liver disease in a general population, the HUNT study. Scand J Gastroenterol. 2023;58(5):505–11.

    Article 
    PubMed 

    Google Scholar
     

  • Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring, Md). 2009;17(9):1696–701.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203(2):581–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Frith J, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. Gerontology. 2009;55(6):607–13.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Poster exhibition. Hepatology international. 2009;3(1):86–220. PMID: 19669375.

  • Abu-Freha N, Cohen B, Weissmann S, Hizkiya R, Abu-Hammad R, Taha G, et al. Comorbidities and Outcomes among Females with Non-Alcoholic Fatty Liver Disease Compared to Males. Biomedicines. 2022;10(11):2908.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8.

    Article 
    PubMed 

    Google Scholar
     

  • Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2010;52(3):913–24.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Doycheva I, Zhang T, Amjad W, Thuluvath PJ. Diabetes and Hepatocellular Carcinoma: Incidence Trends and Impact of Liver Disease Etiology. J Clin Exp Hepatol. 2020;10(4):296–303.

    Article 
    PubMed 

    Google Scholar
     

  • Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–9.

    Article 
    PubMed 

    Google Scholar
     

  • Gokulakrishnan K, Anjana RM, Indulekha K, Anuradha S, Mohan V. Association of hypoadiponectinemia with non-alcoholic fatty liver disease in urban south Indians–(CURES – 81). Indian J Med Res. 2010;132:271–7.

    CAS 
    PubMed 

    Google Scholar
     

  • Liu CC, Hung CL, Shih SC, Ko HJ, Lu YT, Wu YJ, et al. Age-related Differences in the Clinical Presentation, Associated Metabolic Abnormality, and Estimated Cardiovascular Risks from Nonalcoholic Fatty Liver Disease: A Cross-sectional Study from Health Evaluation Center in Taiwan. Int J Gerontol. 2010;4(4):184–91.

    Article 
    CAS 

    Google Scholar
     

  • Manchanayake J, Chitturi S, Nolan C, Farrell GC. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26(3):510–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bianchi G, Bertaccini G, et al. 337 NON ALCOHOLIC FATTY LIVER DISEASE AND AGING. PREVALENCE AND ASSOCIATED FACTORS. J Hepatol. 2010;52:S141. https://search.ebscohost.com/login.aspx?direct=true&db=edsbl&AN=RN268932148&lang=zh-cn&site=eds-live.

  • Shams ME, Al-Gayyar MM, Barakat EA. Type 2 Diabetes Mellitus-Induced Hyperglycemia in patients with NAFLD and normal LFTs: Relationship to Lipid Profile, Oxidative Stress and Pro-Inflammatory Cytokines. Sci Pharm. 2011;79(3):623–34.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Touzin NT, Bush KN, Williams CD, Harrison SA. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease. Ther Adv Gastroenterol. 2011;4(3):169–76.

    Article 

    Google Scholar
     

  • Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol. 2011;3(8):219–27.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nakamura A, Yoneda M, Fujita K, Tajima K, Kikuchi K, Nakajima A, et al. Impact of glucose tolerance on the severity of non-alcoholic steatohepatitis. J Diabetes Investig. 2011;2(6):483–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Valenti L, Nobili V, Al-Serri A, Rametta R, Leathart JB, Zappa MA, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol. 2011;55(6):1409–14.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Loosen SH, Roderburg C, Demir M, Qvartskhava N, Keitel V, Kostev K, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of osteoporosis and bone fractures. Z Gastroenterol. 2022;60(8):1221–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Machida T, Obara T, Miyazaki M, Inoue J, Mano N. Trends in drug prescriptions for type 2 diabetes, hypertension, and dyslipidemia among adults with non-alcoholic fatty liver disease. Ann Hepatol. 2022;27(4):100699.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology (Baltimore, MD). 2012;56(2):605–13.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–31.

    Article 
    PubMed 

    Google Scholar
     

  • Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, et al. Nonalcoholic fatty liver disease in Brazil Clinical and histological profile. Annals Hepatol. 2011;10(1):33–7.

    Article 

    Google Scholar
     

  • Oladunjoye O, Oladunjoye AO, Dhital R, Poudel D, Oladiran OD, Oke IO, et al. A Retrospective Study of Hospitalizations in the USA: Proportion of Hospitalizations With Non-Alcoholic Fatty Liver Disease in Non-Obese Population. Cureus. 2021;13(9):e17869.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tabibian JH, Lazo M, Durazo FA, Yeh HC, Tong MJ, Clark JM. Nonalcoholic fatty liver disease across ethno-racial groups: do Asian-American adults represent a new at-risk population? J Gastroenterol Hepatol. 2011;26(3):501–9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54(4):753–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Barchetta I, Angelico F, Del Ben M, Baroni MG, Pozzilli P, Morini S, et al. Strong association between non alcoholic fatty liver disease (NAFLD) and low 25(OH) vitamin D levels in an adult population with normal serum liver enzymes. BMC Med. 2011;9:85.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying non-alcoholic fatty liver disease. J Gastrointestin Liver Dis. 2012;21(1):53–8.

    PubMed 

    Google Scholar
     

  • Sun L, Lü SZ. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J. 2011;124(6):867–72.

    CAS 
    PubMed 

    Google Scholar
     

  • He S, Bao W, Shao M, Wang W, Wang C, Sun J, et al. Risk factors for non-alcoholic fatty liver disease in a Chinese population. Acta Gastro-Enterol Belg. 2011;74(4):503–8.


    Google Scholar
     

  • Francque S, De Maeght S, Adler M, Deltenre P, de Galocsy C, Orlent H, et al. High prevalence of advanced fibrosis in association with the metabolic syndrome in a Belgian prospective cohort of NAFLD patients with elevated ALT Results of the Belgian NAFLD registry. Acta Gastro-enterol Belg. 2011;74(1):9–16.

    CAS 

    Google Scholar
     

  • Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012;107(2):253–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hep Intl. 2012;6(1):379–85.

    Article 

    Google Scholar
     

  • Bambha K, Belt P, Abraham M, Wilson LA, Pabst M, Ferrell L, et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology (Baltimore, MD). 2012;55(3):769–80.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhang X, Wong VW, Yip TC, Tse YK, Liang LY, Hui VW, et al. Colonoscopy and risk of colorectal cancer in patients with nonalcoholic fatty liver disease: a retrospective territory-wide cohort study. Hepatol Commun. 2021;5(7):1212–23.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Swellam M, Hamdy N. Association of nonalcoholic fatty liver disease with a single nucleotide polymorphism on the gene encoding leptin receptor. IUBMB Life. 2012;64(2):180–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine. 2012;91(6):319–27.

    Article 
    PubMed 

    Google Scholar
     

  • Valantinas J, Apanaviciene DA, Maroziene L, Sveikata A. The prevalence of metabolic risk factors among outpatients with diagnosed nonalcoholic fatty liver disease in Lithuania. Med Sci Monit. 2012;18(5):Ph57-62.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gupta AC, Misra R, Sakhuja P, Singh Y, Basir SF, Sarin SK. Association of adiponectin gene functional polymorphisms (-11377C/G and +45T/G) with nonalcoholic fatty liver disease. Gene. 2012;496(1):63–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fracanzani AL, Valenti L, Russello M, Miele L, Bertelli C, Bellia A, et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS ONE. 2012;7(7):e41183.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hatziagelaki E, Karageorgopoulos DE, Chounta A, Tsiavou A, Falagas ME, Dimitriadis G. Predictors of impaired glucose regulation in patients with non-alcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:351974.

    Article 
    PubMed 

    Google Scholar
     

  • Shi L, Liu ZW, Li Y, Gong C, Zhang H, Song LJ, et al. The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu. Biomed Environ Sci BES. 2012;25(4):383–91.

    PubMed 

    Google Scholar
     

  • Al-hamoudi W, El-Sabbah M, Ali S, Altuwaijri M, Bedewi M, Adam M, et al. Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital-based study. Ann Saudi Med. 2012;32(3):288–92.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Goh SC, Ho EL, Goh KL. Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia. Hep Intl. 2013;7(2):548–54.

    Article 

    Google Scholar
     

  • Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, et al. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: Do they differ from obese or overweight non-alcoholic fatty liver disease? Indian J Endocrinol Metab. 2013;17(4):665–71.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Patel NS, Peterson MR, Lin GY, Feldstein A, Schnabl B, Bettencourt R, et al. Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. Gastroenterol Res Pract. 2013;2013:498296.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abrams GA, Kunde SS, Lazenby AJ, Clements RH. Portal fibrosis and hepatic steatosis in morbidly obese subjects: A spectrum of nonalcoholic fatty liver disease. Hepatol (Baltimore, MD). 2004;40(2):475–83.

    Article 

    Google Scholar
     

  • Ha Y, Hwang SG, Rim KS. The Association between Vitamin D Insufficiency and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Nutrients. 2017;9(8):806.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reddy SK, Hyder O, Marsh JW, Sotiropoulos GC, Paul A, Alexandrescu S, et al. Prevalence of nonalcoholic steatohepatitis among patients with resectable intrahepatic cholangiocarcinoma. J Gastrointest Surg. 2013;17(4):748–55.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hashiba M, Ono M, Hyogo H, Ikeda Y, Masuda K, Yoshioka R, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS ONE. 2013;8(11):e76161.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bakhshipour A, Kaykhaei MA, Moulaei N, Mashhadi MA. Prevalence of coeliac disease in patients with non-alcoholic fatty liver disease. Arab J Gastroenterol. 2013;14(3):113–5.

    Article 
    PubMed 

    Google Scholar
     

  • Ghamar Chehreh ME, Vahedi M, Pourhoseingholi MA, Ashtari S, Khedmat H, Amin M, et al. Estimation of diagnosis and treatment costs of non-alcoholic Fatty liver disease: a two-year observation. Hepat Mon. 2013;13(5):e7382.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58(10):3017–23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Cheah WL, Lee PY, Chang CT, Mohamed HJ, Wong SL. Prevalence of ultrasound diagnosed nonalcoholic fatty liver disease among rural indigenous community of Sarawak and its association with biochemical and anthropometric measures. Southeast Asian J Trop Med Public Health. 2013;44(2):309–17.

    PubMed 

    Google Scholar
     

  • Zelber-Sagi S, Lotan R, Shibolet O, Webb M, Buch A, Nitzan-Kaluski D, et al. Non-alcoholic fatty liver disease independently predicts prediabetes during a 7-year prospective follow-up. Liver Int. 2013;33(9):1406–12.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chang Y, Jung HS, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population. Am J Gastroenterol. 2013;108(12):1861–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hyogo H, Yamagishi S, Maeda S, Fukami K, Ueda S, Okuda S, et al. Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients. Clin Exp Med. 2014;14(1):45–51.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(7):1163-1169.e1161.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Loomba R, Wong R, Fraysse J, Shreay S, Li S, Harrison S, et al. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data. Aliment Pharmacol Ther. 2020;51(11):1149–59.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li Y, Liu L, Wang B, Wang J, Chen D. Hematocrit is associated with fibrosis in patients with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2014;26(3):332–8.

    Article 
    PubMed 

    Google Scholar
     

  • Pulixi EA, Tobaldini E, Battezzati PM, D’Ingianna P, Borroni V, Fracanzani AL, et al. Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic fatty liver disease. PLoS ONE. 2014;9(4):e96349.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Del Ben M, Polimeni L, Baratta F, Bartimoccia S, Carnevale R, Loffredo L, et al. Serum Cytokeratin-18 Is Associated with NOX2-Generated Oxidative stress in patients with Nonalcoholic Fatty Liver. Int J Hepatol. 2014;2014:784985.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ybarra J, Fernández S, Sánchez-Hernández J, Romeo JH, Ballesta-Lopez C, Guell J, et al. Serum alanine aminotransferase predicts interventricular septum thickness and left ventricular mass in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2014;26(6):654–60.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Catanzaro R, Calabrese F, Occhipinti S, Anzalone MG, Italia A, Milazzo M, et al. Nonalcoholic fatty liver disease increases risk for gastroesophageal reflux symptoms. Dig Dis Sci. 2014;59(8):1939–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pemmasani G, Yandrapalli S, Aronow W. Sex differences in cardiovascular diseases and associated risk factors in non-alcoholic steatohepatitis. Am J Cardiovasc Dis. 2020;10(4):362–6.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol. 2014;61(1):75–81.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Rakha EA, Adamson L, Bell E, Neal K, Ryder SD, Kaye PV, et al. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. J Clin Pathol. 2010;63(9):790–5.

    Article 
    PubMed 

    Google Scholar
     

  • Gianotti G, Cenni A, Bianchi G, Masetti M, Zappoli P, Muscari A, et al. Diastolic dysfunction and cardiovascular risk in old subjects: possible association with NAFLD? Arch Gerontol Geriatr. 2014;58(2):188–95.

    Article 
    PubMed 

    Google Scholar
     

  • Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20(47):17932–40.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Andrade GC, Fujise LH, Santana JEF, Oliveira F, Silva Rde C. Non-alcoholic fatty liver disease (NAFLD) in different populations A clinical and epidemiological study sample of São José do Rio Preto. Rev Assoc Med Bras (1992). 2016;62(3):218–26.

    Article 
    PubMed 

    Google Scholar
     

  • Cavalcante LN, Stefano JT, Machado MV, Mazo DF, Rabelo F, Sandes KA, et al. Genetic ancestry analysis in non-alcoholic fatty liver disease patients from Brazil and Portugal. World J Hepatol. 2015;7(10):1433–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shil BC, Saha M, Ahmed F, Dhar SC. Nonalcoholic Fatty Liver Disease: Study of Demographic and Predictive Factors. Euroasian J Hepato-gastroenterol. 2015;5(1):4–6.

    Article 

    Google Scholar
     

  • Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, et al. Nonalcoholic Fatty liver disease is associated With QT prolongation in the general population. J Am Heart Assoc. 2015;4(7):e001820.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent Association Between Improvement of Nonalcoholic Fatty Liver Disease and Reduced Incidence of Type 2 Diabetes. Diabetes Care. 2015;38(9):1673–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chang CC, Wu CL, Su WW, Shih KL, Tarng DC, Chou CT, et al. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep. 2015;5:10096.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Long MT, Wang N, Larson MG, Mitchell GF, Palmisano J, Vasan RS, et al. Nonalcoholic fatty liver disease and vascular function: cross-sectional analysis in the Framingham heart study. Arterioscler Thromb Vasc Biol. 2015;35(5):1284–91.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kwak MS, Kim D, Chung GE, Kim W, Kim YJ, Yoon JH. Cholecystectomy is independently associated with nonalcoholic fatty liver disease in an Asian population. World J Gastroenterol. 2015;21(20):6287–95.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Praveenraj P, Gomes RM, Kumar S, Karthikeyan P, Shankar A, Parthasarathi R, et al. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery. Obes Surg. 2015;25(11):2078–87.

    Article 
    PubMed 

    Google Scholar
     

  • Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS ONE. 2015;10(11):e0142937.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Abdel-Razik A, Mousa N, Shabana W, Yassen AH, Abdelsalam M, Wahba MM, et al. De novo Portal Vein Thrombosis in Non-Cirrhotic Non-Alcoholic Fatty Liver Disease: A 9-Year Prospective Cohort Study. Front Med. 2021;8:650818.

    Article 

    Google Scholar
     

  • Idilman IS, Tuzun A, Savas B, Elhan AH, Celik A, Idilman R, et al. Quantification of liver, pancreas, kidney, and vertebral body MRI-PDFF in non-alcoholic fatty liver disease. Abdom Imaging. 2015;40(6):1512–9.

    Article 
    PubMed 

    Google Scholar
     

  • Du T, Yu X, Yuan G, Zhang J, Sun X. Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk. Cardiovasc Diabetol. 2015;14:144.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, et al. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study. J Gastroenterol. 2015;50(3):350–60.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Huang JF, Yeh ML, Yu ML, Huang CF, Dai CY, Hsieh MY, et al. Hyperuricemia inversely correlates with disease severity in Taiwanese nonalcoholic steatohepatitis patients. PLoS ONE. 2015;10(10):e0139796.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kumar MS, Singh A, Jaryal AK, Ranjan P, Deepak KK, Sharma S, et al. Cardiovascular Autonomic Dysfunction in Patients of Nonalcoholic Fatty Liver Disease. Int J Hepatol. 2016;2016:5160754.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ballestri S, Nascimbeni F, Romagnoli D, Lonardo A. The independent predictors of non-alcoholic steatohepatitis and its individual histological features. Insulin resistance, serum uric acid, metabolic syndrome, alanine aminotransferase and serum total cholesterol are a clue to pathogenesis and candidate targets for treatment. Hepatol Res. 2016;46(11):1074–87.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, et al. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS ONE. 2016;11(9):e0163069.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu KT, Kuo PL, Su SB, Chen YY, Yeh ML, Huang CI, et al. Nonalcoholic fatty liver disease severity is associated with the ratios of total cholesterol and triglycerides to high-density lipoprotein cholesterol. J Clin Lipidol. 2016;10(2):420-425.e421.

    Article 
    PubMed 

    Google Scholar
     

  • Tapper EB, Lai M. Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study. Hepatol (Baltimore, MD). 2016;63(4):1184–9.

    Article 

    Google Scholar
     

  • Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol. 2016;2016:6420408.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Goh GB, Issa D, Lopez R, Dasarathy S, Dasarathy J, Sargent R, et al. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2016;31(5):995–1000.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Petrović G, Bjelaković G, Benedeto-Stojanov D, Nagorni A, Brzački V, Marković-Živković B. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound. Vojnosanit Pregl. 2016;73(10):910–20.

    Article 
    PubMed 

    Google Scholar
     

  • Hagström H, Nasr P, Ekstedt M, Kechagias S, Önnerhag K, Nilsson E, et al. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2017;52(2):159–65.

    Article 
    PubMed 

    Google Scholar
     

  • Conti F, Vukotic R, Foschi FG, Domenicali M, Giacomoni P, Savini S, et al. Transient elastography in healthy subjects and factors influencing liver stiffness in non-alcoholic fatty liver disease: An Italian community-based population study. Dig Liver Dis. 2016;48(11):1357–63.

    Article 
    PubMed 

    Google Scholar
     

  • Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66(1):123–31.

    Article 
    PubMed 

    Google Scholar
     

  • Fracanzani AL, Pisano G, Consonni D, Tiraboschi S, Baragetti A, Bertelli C, et al. Epicardial Adipose Tissue (EAT) thickness is associated with cardiovascular and liver damage in Nonalcoholic fatty liver disease. PLoS ONE. 2016;11(9):e0162473.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Treeprasertsuk S, Piyachaturawat P, Soontornmanokul T, Komolmit P, Wisedopas-Klaikaew N, Tangkijavanich P. Accuracy of noninvasive scoring systems to assess advanced liver fibrosis in Thai patients with nonalcoholic fatty liver disease. Asian Biomed. 2016;10:S49–55-S55.

    CAS 

    Google Scholar
     

  • Wong VW, Wong GL, Yeung JC, Fung CY, Chan JK, Chang ZH, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatol (Baltimore, MD). 2016;63(3):754–63.

    Article 

    Google Scholar
     

  • Dichtel LE, Corey KE, Misdraji J, Bredella MA, Schorr M, Osganian SA, et al. The Association Between IGF-1 Levels and the Histologic Severity of Nonalcoholic Fatty Liver Disease. Clin Transl Gastroenterol. 2017;8(1): e217.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Toshikuni N, Tsuchishima M, Fukumura A, Arisawa T, Tsutsumi M. Associations of fatty liver disease with Hypertension, Diabetes, and Dyslipidemia: comparison between alcoholic and nonalcoholic Steatohepatitis. Gastroenterol Res Pract. 2017;2017:9127847.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Chan WK, Treeprasertsuk S, Imajo K, Nakajima A, Seki Y, Kasama K, et al. Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative. Aliment Pharmacol Ther. 2018;47(6):816–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • van den Berg EH, Gruppen EG, James RW, Bakker SJL, Dullaart RPF. Serum paraoxonase 1 activity is paradoxically maintained in nonalcoholic fatty liver disease despite low HDL cholesterol. J Lipid Res. 2019;60(1):168–75.

    Article 
    PubMed 

    Google Scholar
     

  • Wen X, Wang S, Taveira TH, Akhlaghi F. Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS ONE. 2021;16(9):e0251665.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lee HW, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, et al. Prevalence and predictors of significant fibrosis among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2017;62(8):2150–8.

    Article 
    PubMed 

    Google Scholar
     

  • Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, et al. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver Int. 2017;37(9):1389–96.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Singh A, Kumar MS, Jaryal AK, Ranjan P, Deepak KK, Sharma S, et al. Diabetic status and grade of nonalcoholic fatty liver disease are associated with lower baroreceptor sensitivity in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2017;29(8):956–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Weinstein G, Zelber-Sagi S, Preis SR, Beiser AS, DeCarli C, Speliotes EK, et al. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study. JAMA Neurol. 2018;75(1):97–104.

    Article 
    PubMed 

    Google Scholar
     

  • Morio R, Hyogo H, Hatooka M, Morio K, Kan H, Kobayashi T, et al. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. J Gastroenterol. 2017;52(2):253–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Patel YA, Gifford EJ, Glass LM, McNeil R, Turner MJ, Han B, et al. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration. Aliment Pharmacol Ther. 2018;47(2):268–78.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Dallio M, Masarone M, Errico S, Gravina AG, Nicolucci C, Di Sarno R, et al. Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study. Aliment Pharmacol Ther. 2018;47(6):826–37.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Jun DW, Kim SG, Park SH, Jin SY, Lee JS, Lee JW, et al. External validation of the non-alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients. J Gastroenterol Hepatol. 2017;32(5):1094–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim S, Chang Y, Sung E, Kim CH, Yun KE, Jung HS, et al. Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. PLoS ONE. 2017;12(10): e0184506.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tasneem AA, Luck NH, Majid Z. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Trop Doct. 2018;48(2):107–12.

    Article 
    PubMed 

    Google Scholar
     

  • Bae JC, Kim SK, Han JM, Kwon S, Lee DY, Kim J, et al. Additive effect of non-alcoholic fatty liver disease on the development of diabetes in individuals with metabolic syndrome. Diabetes Res Clin Pract. 2017;129:136–43.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Abdeldyem SM, Goda T, Khodeir SA, Abou Saif S, Abd-Elsalam S. Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome. J Clin Lipidol. 2017;11(4):915–9.

    Article 
    PubMed 

    Google Scholar
     

  • Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis. 2018;50(4):370–7.

    Article 
    PubMed 

    Google Scholar
     

  • Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study. Hepatol Commun. 2018;2(1):48–57.

    Article 
    PubMed 

    Google Scholar
     

  • Peng H, Wang M, Pan L, Cao Z, Yao Z, Chen Q, et al. Associations of serum multivitamin levels with the risk of non-alcoholic fatty liver disease A population-based cross-sectional study in U.S. adults. Front Nut. 2022;9:962705.

    Article 

    Google Scholar
     

  • Janovsky C, Cesena FH, Valente VAT, Conceição RDO, Santos RD, Bittencourt MS. Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. Eur Thyroid J. 2018;7(6):302–7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yoneda M, Yamamoto T, Honda Y, Imajo K, Ogawa Y, Kessoku T, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. J Gastroenterol. 2021;56(11):1022–32.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Shahab O, Biswas R, Paik J, Bush H, Golabi P, Younossi ZM. Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. Hepatol Commun. 2018;2(10):1227–34.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Patel P, Hossain F, Horsfall LU, Banh X, Hayward KL, Williams S, et al. A pragmatic approach identifies a high Rate of Nonalcoholic fatty liver disease with advanced Fibrosis in diabetes clinics and at-risk populations in primary care. Hepatol Commun. 2018;2(8):893–905.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Akuta N, Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, et al. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan. BMC Gastroenterol. 2018;18(1):165.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kwon YJ, Kim JH, Jung DH. Association between nonalcoholic fatty liver disease and intraocular pressure in Korean adults. J Glaucoma. 2018;27(12):1099–104.

    Article 
    PubMed 

    Google Scholar
     

  • Qin S, Wang S, Wang X, Wang J. Liver stiffness assessed by transient elastography as a potential indicator of chronic kidney disease in patients with nonalcoholic fatty liver disease. J Clin Lab Anal. 2019;33(2):e22657.

    Article 
    PubMed 

    Google Scholar
     

  • Chung GE, Youn J, Kim YS, Lee JE, Yang SY, Lim JH, et al. Dietary patterns are associated with the prevalence of nonalcoholic fatty liver disease in Korean adults. Nutrition. 2019;62:32–8.

    Article 
    PubMed 

    Google Scholar
     

  • De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, et al. Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent. Front Gastroenterol. 2018;9(2):115–21.

    Article 

    Google Scholar
     

  • Koo BK, Um SH, Seo DS, Joo SK, Bae JM, Park JH, et al. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease. Liver Int. 2018;38(4):695–705.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Mazzotti A, Caletti MT, Brodosi L, Di Domizio S, Forchielli ML, Petta S, et al. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. J Hepatol. 2018;69(5):1155–63.

    Article 
    PubMed 

    Google Scholar
     

  • Kimura T, Tanaka N, Fujimori N, Sugiura A, Yamazaki T, Joshita S, et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World J Gastroenterol. 2018;24(13):1440–50.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Labenz C, Huber Y, Kalliga E, Nagel M, Ruckes C, Straub BK, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109–16.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pardhe BD, Shakya S, Bhetwal A, Mathias J, Khanal PR, Pandit R, et al. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. BMC Gastroenterol. 2018;18(1):109.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tuttolomondo A, Petta S, Casuccio A, Maida C, Corte VD, Daidone M, et al. Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovasc Diabetol. 2018;17(1):28.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li H, Hu B, Wei L, Zhou L, Zhang L, Lin Y, et al. Non-alcoholic fatty liver disease is associated with stroke severity and progression of brainstem infarctions. Eur J Neurol. 2018;25(3):577-e534.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ooi GJ, Burton PR, Bayliss J, Raajendiran A, Earnest A, Laurie C, et al. Effect of Body Mass Index, Metabolic Health and Adipose Tissue inflammation on the severity of non-alcoholic fatty liver disease in Bariatric surgical patients: a prospective study. Obes Surg. 2019;29(1):99–108.

    Article 
    PubMed 

    Google Scholar
     

  • de la Aller Fuente R, Mora Cuadrado N, Tafur C, de la López Gómez JJ, Gómez Cuesta S, García Sánchez MC, et al. Histopathological differences in patients with biopsyproven nonalcoholic fatty liver disease with and without type 2 diabetes. Endocrinol Diabetes nutr. 2018;65(6):354–60.

    Article 

    Google Scholar
     

  • Rabelo F, Stefano JT, Cavaleiro AM, Lima RVC, de Campos Mazo DF, Carrilho FJ, et al. Association between the CYBA and NOX4 genes of NADPH oxidase and its relationship with metabolic syndrome in non-alcoholic fatty liver disease in Brazilian population. Hepatobiliary Pancreat Dis Int. 2018;17(4):330–5.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nigam P, Pandey RP, Pawar M, Indurkar M. CLINICAL PROFILE OF NAFLD PATIENTS AND ITS CORRELATION WITH METABOLIC SYNDROME. J Evol Med Dent Sci. 2018;7(4):433–6.

    Article 
    CAS 

    Google Scholar
     

  • Omrani HR, Golmohamadi S, Asadi N. Non-Alcoholic Fatty Liver Disease and Associated Risk Factors among Hemodialysis Patients. 2018. https://doi.org/10.5742/MEWFM.2018.93354. https://search.ebscohost.com/login.aspx?direct=true&db=edsaml&AN=edsaml.117456&lang=zh-cn&site=eds-live.

  • Gordon SC, Fraysse J, Li S, Ozbay AB, Wong RJ. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients. Am J gastroenterol. 2020;115(4):562–74.

    Article 

    Google Scholar
     

  • Shah AS, Khan S, Rahim H, Chishti KA, Khan AG. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa Pakistan. Pak J Pharm Sci. 2018;31(1):193–8.

    PubMed 

    Google Scholar
     

  • Chen HJ, Yang HY, Hsueh KC, Shen CC, Chen RY, Yu HC, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease: A population-based retrospective cohort study. Medicine. 2018;97(42):e12835.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Alam S, Anam K, Islam S, Mustafa G, Mamun AA, Ahmad N. Clinical, anthropometric, biochemical and histological character of nonalcoholic fatty liver disease without Insulin Resistance. J Clin Exp Hepatol. 2019;9(2):176–81.

    Article 
    PubMed 

    Google Scholar
     

  • Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol. 2019;6(1):e000295.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Khammas ASA, Hassan HA, Salih SQM, Kadir H, Ibrahim RM, Nasir NNM, et al. Prevalence and risk factors of sonographically detected non alcoholic fatty liver disease in a screening centre in Klang Valley, Malaysia: an observational cross-sectional study. Porto Biomed J. 2019;4(2):e31.

    Article 
    PubMed 

    Google Scholar
     

  • Moolla A, Motohashi K, Marjot T, Shard A, Ainsworth M, Gray A, et al. A multidisciplinary approach to the management of NAFLD is associated with improvement in markers of liver and cardio-metabolic health. Front Gastroenterol. 2019;10(4):337–46.

    Article 

    Google Scholar
     

  • Nabi O, Lacombe K, Boursier J, Mathurin P, Zins M, Serfaty L. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. Gastroenterol. 2020;159(2):791-793.e792.

    Article 
    CAS 

    Google Scholar
     

  • Shida T, Oshida N, Oh S, Okada K, Shoda J. Progressive reduction in skeletal muscle mass to visceral fat area ratio is associated with a worsening of the hepatic conditions of non-alcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:495–503.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tsou P, Wu CJ. Serum Vitamin E Levels of Adults with Nonalcoholic Fatty Liver Disease: An Inverse Relationship with All-Cause Mortality in Non-Diabetic but Not in Pre-Diabetic or Diabetic Subjects. J Clin Med. 2019;8(7):1057.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Azuma S, Asahina Y, Kakinuma S, Azuma K, Miyoshi M, Inoue E, et al. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Dig Dis. 2019;37(3):247–54.

    Article 
    PubMed 

    Google Scholar
     

  • Blackett JW, Verna EC, Lebwohl B. Increased Prevalence of Colorectal Adenomas in Patients with Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. Dig Dis. 2020;38(3):222–30.

    Article 
    PubMed 

    Google Scholar
     

  • Cho HJ, Hwang S, Park JI, Yang MJ, Hwang JC, Yoo BM, et al. Improvement of Nonalcoholic fatty liver disease reduces the risk of type 2 Diabetes Mellitus. Gut and liver. 2019;13(4):440–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jaafar RF, Hajj Ali AM, Zaghal AM, Kanso M, Habib SG, Halaoui AF, et al. Fibroscan and low-density lipoprotein as determinants of severe liver fibrosis in diabetic patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2019;31(12):1540–4.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim D, Kim W, Joo SK, Kim JH, Harrison SA, Younossi ZM, et al. Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease. Liver Int. 2019;39(2):332–41.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Maev IV, Samsonov AA, Palgova LK, Pavlov CS, Shirokova E, Starostin KM. Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. BMJ Open Gastroenterol. 2019;6(1):e000307.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Udelsman BV, Corey KE, Lindvall C, Gee DW, Meireles OR, Hutter MM, et al. Risk factors and prevalence of liver disease in review of 2557 routine liver biopsies performed during bariatric surgery. Surg Obes Relat Dis. 2019;15(6):843–9.

    Article 
    PubMed 

    Google Scholar
     

  • Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories. Hypertension. 2020;76(2):562–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Yılmaz Y, Kanı HT, Demirtaş C, Kaya E, Sapmaz AF, Qutranji L, et al. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. Turkish J Gastroenterol. 2019;30(10):892–8.

    Article 

    Google Scholar
     

  • Han J, Wang Y, Yuan Z, Liu L, Zhao M, Guan Q, et al. Nonalcoholic fatty liver disease represents a greater metabolic burden in patients with atherosclerosis: A cross-sectional study. Medicine. 2019;98(11):e14896.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Mahamid M, Khoury T, Mahamid B, Sbeit W, Mari A, Nseir W. The interplay between abdominal aortic aneurysm, metabolic syndrome and fatty liver disease: a retrospective case-control study. Diabetes Metabolic Syndr Obes. 2019;12:1743–9.

    Article 
    CAS 

    Google Scholar
     

  • Zhou X, Li Y, Zhang X, Guan YY, Puentes Y, Zhang F, et al. Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort. Diabetes Metab Res Rev. 2019;35(5):e3156.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wu J, Zeng C, Yang Z, Li X, Lei G, Xie D, et al. Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study. J Am Coll Nutr. 2020;39(2):103–11.

    Article 
    PubMed 

    Google Scholar
     

  • Gawrieh S, Wilson LA, Cummings OW, Clark JM, Loomba R, Hameed B, et al. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. Am J Gastroenterol. 2019;114(10):1626–35.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Barb D, Bril F, Kalavalapalli S, Cusi K. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. J Clin Endocrinol Metab. 2019;104(8):3327–36.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang X, Zhou X, Han X, Fu Z, Wang L, Li Y, et al. The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population. Metab Syndr Relat Disord. 2020;18(6):284–90.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Luo K, Bian J, Wang Q, Wang J, Chen F, Li H, et al. Association of obesity with chronic kidney disease in elderly patients with nonalcoholic fatty liver disease. Turkish J Gastroenterol. 2019;30(7):611–5.

    Article 

    Google Scholar
     

  • Simon TG, Trejo MEP, McClelland R, Bradley R, Blaha MJ, Zeb I, et al. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis. Int J Cardiol. 2018;259:198–204.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li Y, He F, He Y, Pan X, Wu Y, Hu Z, et al. Dose-response association between physical activity and non-alcoholic fatty liver disease: a case-control study in a Chinese population. BMJ Open. 2019;9(3):e026854.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tu S, Zhao R, Fang H, Wang L, Shao A, Sheng J. Association between Non-Alcoholic Fatty Liver Disease and Intracerebral Hemorrhage. Cell Transplant. 2019;28(8):1033–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Önnerhag K, Dreja K, Nilsson PM, Lindgren S. Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities. Clin Res Hepatol Gastroenterol. 2019;43(5):542–50.

    Article 
    PubMed 

    Google Scholar
     

  • Weinstein G, Davis-Plourde K, Himali JJ, Zelber-Sagi S, Beiser AS, Seshadri S. Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study. Liver Int. 2019;39(9):1713–21.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ulasoglu C, Enc FY, Kaya E, Yilmaz Y. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels. J Gastrointestin Liver Dis. 2019;28(4):427–31.

    Article 
    PubMed 

    Google Scholar
     

  • Zhao H, Hu B. Risk factors for Non-alcoholic Fatty Liver Disease in Chinese population: a five-year follow-up study. Iran Red Crescent Med J. 2019;21(7):e91064.

    Article 

    Google Scholar
     

  • Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, et al. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle-aged patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2019;34(11):2011–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Niriella MA, Kasturiratne A, Pathmeswaran A, De Silva ST, Perera KR, Subasinghe S, et al. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka. Hep Intl. 2019;13(3):314–22.

    Article 

    Google Scholar
     

  • Rong HJ, Meng CR, Chen ZY, Xue L. Biomarkers of non-alcoholic fatty liver disease in a Chinese population: a cross-sectional survey. Int J Clin Exp Med. 2019;12(2):1827–34.

    CAS 

    Google Scholar
     

  • Poynard T, Peta V, Deckmyn O, Pais R, Ngo Y, Charlotte F, et al. Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Eur J Gastroenterol Hepatol. 2020;32(8):998–1007.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • McGhee-Jez AE, Chervoneva I, Yi M, Ahuja A, Nahar R, Shah S, et al. Nonalcoholic fatty liver disease after Pancreaticoduodenectomy for a cancer diagnosis. J Pancreat Cancer. 2021;7(1):23–30.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tahir F, Majid Z, Majid B, Ahmed J, Zaman A, Tariq M, et al. Anthropometric Measurements and Lifestyle Characteristics of Individuals with Non-alcoholic Fatty Liver Disease. Cureus. 2020;12(2):e7016.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bian H, Zhu X, Xia M, Yan H, Chang X, Li X, et al. Impact of type 2 diabetes on nonalcoholic steatohepatitis and advanced fibrosis in patients with nonalcoholic fatty liver disease. Endocr Pract. 2020;26(4):444–53-453.

    Article 
    PubMed 

    Google Scholar
     

  • Clough GF, Chipperfield AJ, Thanaj M, Scorletti E, Calder PC, Byrne CD. Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. Front Physiol. 2020;11:551.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kogiso T, Sagawa T, Kodama K, Taniai M, Hashimoto E, Tokushige K. Development and course of diabetes according to genetic factors and diabetes treatment among patients with nonalcoholic fatty liver disease. Nutrition. 2021;83:111080.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • An JN, Joo SK, Koo BK, Kim JH, Oh S, Kim W. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. Hep Intl. 2020;14(5):798–807.

    Article 

    Google Scholar
     

  • Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, et al. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol. 2020;12(10):792–806.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Qiao ZP, Zheng KI, Zhu PW, Gao F, Zheng MH. Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. Nutr Metab Cardiovasc Dis. 2020;30(10):1820–5. PMID: 32636124.

  • Hirose S, Matsumoto K, Tatemichi M, Tsuruya K, Anzai K, Arase Y, et al. Nineteen-year prognosis in Japanese patients with biopsy-proven nonalcoholic fatty liver disease: Lean versus overweight patients. PLoS ONE. 2020;15(11):e0241770.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ishiba H, Sumida Y, Seko Y, Tanaka S, Yoneda M, Hyogo H, et al. Type IV Collagen 7S is the most accurate test for identifying advanced Fibrosis in NAFLD with type 2 diabetes. Hepatol Commun. 2021;5(4):559–72.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xia W, Yang N, Li Y. Analysis of Risk Factors for Adverse Cardiovascular Events in Elderly Patients with Acute Myocardial Infarction and Non-Alcoholic Fatty Liver Disease (NAFLD). Med Sci Monit. 2020;26:e922913.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Afolabi PR, Scorletti E, Calder PC, Byrne CD. Factors independently associated with cardiorespiratory fitness in patients with non-alcoholic fatty liver disease. Liver Int. 2020;40(12):2998–3007.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ma C, Liu Y, He S, Zeng J, Li P, Ma C, et al. C-Peptide: A Mediator of the Association Between Serum Uric Acid to Creatinine Ratio and Non-Alcoholic Fatty Liver Disease in a Chinese Population With Normal Serum Uric Acid Levels. Front Endocrinol. 2020;11:600472.

    Article 

    Google Scholar
     

  • Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608–12.

    Article 
    PubMed 

    Google Scholar
     

  • Ahmed HS, Pedersen N, Jayanna MB, Ten Eyck P, Sanchez A, Murali AR. Predictive Factors and Time to Development of Hepatic Decompensation in Patients with Non-alcoholic Fatty Liver Disease. J Gen Intern Med. 2020;35(5):1523–9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Giraldi L, Miele L, Aleksovska K, Manca F, Leoncini E, Biolato M, et al. Mediterranean diet and the prevention of non-alcoholic fatty liver disease: results from a case-control study. Eur Rev Med Pharmacol Sci. 2020;24(13):7391–8.

    CAS 
    PubMed 

    Google Scholar
     

  • Linge J, Ekstedt M, Dahlqvist LO. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD. JHEP Rep. 2021;3(1):100197.

    Article 
    PubMed 

    Google Scholar
     

  • Li CH, Chou YT, Shen WC, Lu FH, Yang YC, Wu JS, et al. Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7–6.4% in a Chinese population. J Diabetes Investig. 2020;11(5):1336–43.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Su Y, Liu Z, Yang L, Li Y, Jiang S, Yao H, et al. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. Clin Res Hepatol Gastroenterol. 2020;44(6):894–904.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sun DQ, Jin Y, Wang TY, Zheng KI, Rios RS, Zhang HY, et al. MAFLD and risk of CKD. Metabolism. 2021;115:154433.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Miller A, McNamara J, Hummel SL, Konerman MC, Tincopa MA. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction. Sci Rep. 2020;10(1):12440.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sinn DH, Kang D, Chang Y, Ryu S, Cho SJ, Paik SW, et al. Non-alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study. J Gastroenterol Hepatol. 2020;35(5):833–9.

    Article 
    PubMed 

    Google Scholar
     

  • Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, et al. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver international : official journal of the International Association for the Study of the Liver. 2020;40(9):2082–9.

    Article 
    PubMed 

    Google Scholar
     

  • Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M, et al. Prevalence, risk factors and metabolic profile of the non-obese and obese non-alcoholic fatty liver disease in a rural community of South Asia. BMJ Open Gastroenterol. 2020;7(1):e000535.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang X, Han F, Ji Z, Shen L, Shen Y. Association between Non-alcoholic Fatty Liver Disease and the Severity of Coronary Artery Stenosis in Eastern Chinese Population. Hepat Mon. 2021;21(11):e122772.

  • Iritani S, Akuta N, Kawamura Y, Kajiwara A, Kasuya K, Fujiyama S, et al. Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease. BMC Gastroenterol. 2020;20(1):368.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Stefano JT, Guedes LV, de Souza AAA, Vanni DS, Alves VAF, Carrilho FJ, et al. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol. 2021;20:100253.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020;71(3):808–19.

    Article 
    PubMed 

    Google Scholar
     

  • Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. Liver Int. 2022;42(4):820–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Boga S, Koksal AR, Sen İ, Kurul Yeniay M, Yilmaz Ozguven MB, Serin E, et al. Liver and pancreas “Castor and Pollux” regarding the relationship between hepatic steatosis and pancreas exocrine insufficiency. Pancreatology. 2020;20(5):880–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Miele L, Grattagliano I, Lapi F, Dajko M, De Magistris A, Liguori A, et al. Non-alcoholic fatty liver disease and the risk of fibrosis in Italian primary care services: GPS-NAFLD Study: GPS-NAFLD Study. Liver Int. 2022;42(12):2632–45.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ng CH, Chan KE, Chin YH, Zeng RW, Tsai PC, Lim WH, et al. The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;28(3):565–74.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Adrian T, Sørensen IMH, Knop FK, Bro S, Ballegaard ELF, Nordestgaard BG, et al. Prevalence of non-alcoholic fatty liver disease in patients with chronic kidney disease: a cross-sectional study. Nephrol Dial Transplant. 2022;37(10):1927–34.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Dai W, Zhang Z, Zhao S. The risk of type 2 diabetes and Coronary artery disease in non-obese Patients with non-alcoholic fatty liver disease: a cohort study. Front cardiovasc med. 2021;8:680664.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Hu PF, Zeng X, Zou ZY, Tang W, Guo YB, Yuan ZL, et al. The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: a population-based cross-sectional study. Hepatobiliary Surg Nutr. 2021;10(6):811–24.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Alswat K, Sanai FM, Al-Hamoudi W, Ismail M, Dahlan Y, AlGhamdi HS, et al. Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry. Diabetes Metab Syndr Obes. 2021;14:1167–75.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Eldafashi N, Darlay R, Shukla R, McCain MV, Watson R, Liu YL, et al. A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? Cancers. 2021;13(6):1412.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Higuera-de-la-Tijera F, Córdova-Gallardo J, Buganza-Torio E, Barranco-Fragoso B, Torre A, Parraguirre-Martínez S, et al. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value. Dig Dis Sci. 2021;66(12):4501–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Johnson PC, Cochet AA, Gore RS, Harrison SA, Magulick JP, Aden JK, et al. Early Cardiac Dysfunction in Biopsy-proven Nonalcoholic Fatty Liver Disease. Korean J Gastroenterol. 2021;78(3):161–7.

    Article 
    PubMed 

    Google Scholar
     

  • Satapathy SK, Tran QT, Kovalic AJ, Bontha SV, Jiang Y, Kedia S, et al. Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation. Clin Transl Gastroenterol. 2021;12(2):e00302.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yang RX, Zou ZS, Zhong BH, Deng H, He FP, Shi JP, et al. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. Hepatobiliary Pancreat Dis Int. 2021;20(5):426–32.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Chen LW, Huang MS, Shyu YC, Chien RN. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study. Kaohsiung J Med Sci. 2021;37(9):819–27.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, et al. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep. 2021;11(1):13844.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Anstee QM, Hallsworth K, Lynch N, Hauvespre A, Mansour E, Kozma S, et al. Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. JHEP Rep. 2022;4(1):100411.

    Article 
    PubMed 

    Google Scholar
     

  • Siddiqui B, Kamran M, Tikmani SS, Azmat R, Mushtaq Z, Zafar SB, et al. Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study. SAGE Open Med. 2021;9:20503121211025420.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Yao VJH, Sun M, Rahman AA, Samuel Z, Chan J, Zheng E, et al. Comparative analysis of metabolic risk factors for progression of non-alcoholic fatty liver disease. Clin Exp Hepatol. 2021;7(2):241–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Moon JH, Koo BK, Kim W. Non-alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey. J Cachexia Sarcopenia Muscle. 2021;12(4):964–72.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Song E, Kim JA, Roh E, Yu JH, Kim NH, Yoo HJ, et al. Long Working Hours and Risk of Nonalcoholic Fatty Liver Disease: Korea National Health and Nutrition Examination Survey VII. Front Endocrinol. 2021;12:647459.

    Article 

    Google Scholar
     

  • Funuyet-Salas J, Pérez-San-Gregorio M, Martín-Rodríguez A, Romero-Gómez M. Quality of Life and Coping in Nonalcoholic Fatty Liver Disease: Influence of Diabetes and Obesity. Int J Environ Res Public health. 2021;18(7):3503.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Nguyen AL, Park H, Nguyen P, Sheen E, Kim YA, Nguyen MH. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA. Dig Dis Sci. 2019;64(3):698–707.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hu Z, Li Y, Yang Y, Yu W, Xie W, Song G, et al. Serum lipids mediate the relationship of multiple polyaromatic hydrocarbons on non-alcoholic fatty liver disease: A population-based study. Sci Total Environ. 2021;780:146563.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vittal A, Shapses M, Sharma B, Sharma D, Sun Q, Sampson M, et al. Lipoprotein Insulin Resistance Index Reflects Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2021;5(4):589–97.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bayliss J, Ooi GJ, De Nardo W, Shah YJH, Montgomery MK, McLean C, et al. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes. Front Endocrinol. 2021;12:642432.

    Article 

    Google Scholar
     

  • Roberts SK, Majeed A, Glenister K, Magliano D, Lubel JS, Bourke L, et al. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study. Med J Aust. 2021;215(2):77–82.

    Article 
    PubMed 

    Google Scholar
     

  • Baikpour M, Ozturk A, Dhyani M, Mercaldo ND, Pierce TT, Grajo JR, et al. Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Nonalcoholic Fatty Liver Disease. AJR Am J Roentgenol. 2020;214(4):786–91.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012;36(8):772–81.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol. 2009;104(4):861–7.

    Article 
    PubMed 

    Google Scholar
     

  • Pereira E, Paula DP, de Araujo BP, da Fonseca MJM, Diniz M, Daliry A, et al. Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study. World J Gastroenterol. 2021;27(29):4913–28.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Emamat H, Ghalandari H, Totmaj AS, Tangestani H, Hekmatdoost A. Calcium to magnesium intake ratio and non-alcoholic fatty liver disease development: a case-control study. BMC Endocr Disord. 2021;21(1):51.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Irvine KM, Okano S, Patel PJ, Horsfall LU, Williams S, Russell A, et al. Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep. 2021;11(1):2858.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lum JHM, Cheah MCC, Leow WQ, Wan WK, Lim TKH, Chow WC, et al. Clinical profile of non-alcoholic fatty liver disease in nonobese patients. J Gastroenterol Hepatol. 2021;36(1):257–61.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zhu K, Guo Y, Zhao C, Kang S, Li J, Wang J, et al. Etiology Exploration of Non-alcoholic Fatty Liver Disease From Traditional Chinese Medicine Constitution Perspective: A Cross-Sectional Study. Front Public Health. 2021;9:635818.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhang J, Xu Q, Lai F, Chen N, Lin M, Liu Y, et al. Joint associations of metabolically healthy abdominal obesity and non-alcoholic fatty liver disease with prediabetes and diabetes in Chinese adults. BMJ Open Diabetes Res Care. 2021;9(1):e002362.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Belinchón-Romero I, Bellot P, Romero-Pérez D, Herraiz-Romero I, Marco F, Frances R, et al. Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients. Sci Rep. 2021;11(1):8593.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Labenz C, Kostev K, Armandi A, Galle PR, Schattenberg JM. Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. United Eur Gastroenterol J. 2021;9(7):829–36.

    Article 
    CAS 

    Google Scholar
     

  • Huang R, Fan JG, Shi JP, Mao YM, Wang BY, Zhao JM, et al. Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey. Health Qual Life Outcomes. 2021;19(1):140.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Khayyat YM. Lean non-alcoholic fatty liver disease and associated metabolic disturbance: A Saudi Arabian cross-sectional study. Physiol Rep. 2021;9(14):e14949.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • García-Compeán D, Villarreal-Pérez JZ, Cavazos MEO, Lavalle-Gonzalez FJ, Borjas-Almaguer OD, Del Cueto-Aguilera AN, et al. Prevalence of liver fibrosis in an unselected general population with high prevalence of obesity and diabetes mellitus Time for screening? Annals Hepatol. 2020;19(3):258–64.

    Article 

    Google Scholar
     

  • Sang C, Yan H, Chan WK, Zhu X, Sun T, Chang X, et al. Diagnosis of Fibrosis Using Blood Markers and Logistic Regression in Southeast Asian Patients With Non-alcoholic Fatty Liver Disease. Front Med. 2021;8:637652.

    Article 

    Google Scholar
     

  • Gerber Y, VanWagner LB, Yaffe K, Terry JG, Rana JS, Reis JP, et al. Non-alcoholic fatty liver disease and cognitive function in middle-aged adults: the CARDIA study. BMC Gastroenterol. 2021;21(1):96.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Blomdahl J, Nasr P, Ekstedt M, Kechagias S. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus. Metabol Clin Exp. 2021;115:154439.

    Article 
    CAS 

    Google Scholar
     

  • Zhang X, Heredia NI, Balakrishnan M, Thrift AP. Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017–2018. PLoS ONE. 2021;16(6):e0252164.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Simon TG, Roelstraete B, Sharma R, Khalili H, Hagström H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology. 2021;74(5):2410–23.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Wang G, Wu S, Wu C, Zhang Q, Wu F, Yu B, et al. Association between non-alcoholic fatty liver disease with the susceptibility and outcome of COVID-19: A retrospective study. J Cell Mol Med. 2021;25(24):11212–20.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang B, Zhao Z, Liu S, Wang S, Chen Y, Xu Y, et al. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease. Diabetes Res Clin Pract. 2021;177:108873.

    Article 
    PubMed 

    Google Scholar
     

  • Nass KJ, van den Berg EH, Faber KN, Schreuder T, Blokzijl H, Dullaart RPF. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study. Metabol Clin Exp. 2017;72:37–46.

    Article 
    CAS 

    Google Scholar
     

  • Younossi ZM, Felix S, Jeffers T, Younossi E, Nader F, Pham H, et al. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2021;4(9):e2123923.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Rodriguez LA, Shiboski SC, Bradshaw PT, Fernandez A, Herrington D, Ding J, et al. Predicting Non-Alcoholic Fatty Liver Disease for Adults Using Practical Clinical Measures: Evidence from the Multi-ethnic Study of Atherosclerosis. J Gen Intern Med. 2021;36(9):2648–55.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Baratta F, Ferro D, Pastori D, Colantoni A, Cocomello N, Coronati M, et al. Open issues in the transition from NAFLD to MAFLD: the experience of the Plinio study. Int J Environ Res Public Health. 2021;18(17):8993.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • van Kleef LA, Ayada I, Alferink LJM, Pan Q, de Knegt RJ. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study. Hepatology. 2022;75(2):419–29.

    Article 
    PubMed 

    Google Scholar
     

  • Huang Q, Zou X, Wen X, Zhou X, Ji L. NAFLD or MAFLD: which has closer association with all-cause and cause-specific mortality?-results from NHANES III. Front Med. 2021;8:693507.

    Article 

    Google Scholar
     

  • Wu W, Xiang J, Chen X. Association between diabetes Mellitus and all-cause and Cardiovascular mortality among individuals with ultrasound-defined non-alcoholic fatty liver disease. Front Endocrinol. 2021;12:773342.

    Article 

    Google Scholar
     

  • Younes R, Govaere O, Petta S, Miele L, Tiniakos D, Burt A, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2022;71(2):382–90.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ghumman NA, Qamar MA, Khurrum N, Khan ZA, Mustafa ZU, Irshad F. Clinical Symptomatology and Laboratory Diagnosis of Nonalcoholic Chronic Fatty Liver Disease. Pak J Med Sci. 2021;15:2371–2.


    Google Scholar
     

  • Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Park H, Yoon EL, Cho S, Jun DW, Nah EH. Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease. Gut. 2022;71(5):1035–6.

    Article 
    PubMed 

    Google Scholar
     

  • Alsuhaibani KA, Althunayyan FS, Alsudays AM, Alharbi AA, Aljarallah BM. Nonalcoholic fatty liver disease in lean and obese patients in Saudi patients from a single center. J Family Med Prim Care. 2021;10(9):3381–6.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, et al. Glycemic control predicts severity of Hepatocyte Ballooning and Hepatic Fibrosis in nonalcoholic fatty liver Disease. Hepatology. 2021;74(3):1220–33.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Pinyopornpanish K, Khoudari G, Saleh MA, Angkurawaranon C, Pinyopornpanish K, Mansoor E, et al. Hepatocellular carcinoma in nonalcoholic fatty liver disease with or without cirrhosis: a population-based study. BMC Gastroenterol. 2021;21(1):394.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Holmer M, Ekstedt M, Nasr P, Zenlander R, Wester A, Tavaglione F, et al. Effect of common genetic variants on the risk of cirrhosis in non-alcoholic fatty liver disease during 20 years of follow-up. Liver Int. 2022;42(12):2769–80.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Grupper A, Rabinowich A, Ben Shabat I, Tzadok R, Schwartz D, Schwartz IF, et al. Nonalcoholic fatty liver disease before Kidney Transplantation Correlates with new onset diabetes and poor Metabolic outcomes. Am J Nephrol. 2022;53(8–9):636–45.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Golabi P, Paik JM, Harring M, Younossi E, Kabbara K, Younossi ZM. Prevalence of high and moderate risk Nonalcoholic fatty liver disease among adults in the United States, 1999–2016. Clin Gastroenterol Hepatol. 2022;20(12):2838-2847.e2837.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Elhence A, Anand A, Biswas S, Vaishnav M, Yadav R, Das P, et al. Compensated advanced chronic liver disease in nonalcoholic fatty liver disease: two-step strategy is better than Baveno Criteria. Dig Dis Sci. 2023;68(3):1016–25.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Damjanovska S, Karb DB, Tripathi A, Asirwatham J, Delozier S, Perez JA, et al. Accuracy of Ultrasound Elastography and Fibrosis-4 Index (FIB-4) in Ruling Out Cirrhosis in obese non-alcoholic fatty liver Disease (NAFLD) Patients. Cureus. 2022;14(9):e29445.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Ferrari-Cestari M, Okano S, Patel PJ, Horsfall LU, Keshvari S, Hume DA, et al. Serum CC-Chemokine Ligand 2 Is associated with visceral adiposity but not fibrosis in patients with non-alcoholic fatty liver disease. Dig Dis. 2023;41(3):439–46.

    Article 
    PubMed 

    Google Scholar
     

  • Thrift AP, Nguyen TH, Pham C, Balakrishnan M, Kanwal F, Loomba R, et al. The Prevalence and Determinants of NAFLD and MAFLD and Their Severity in the VA Primary Care Setting. Clin Gastroenterol Hepatol. 2023;21(5):1252-1260.e1255.

    Article 
    PubMed 

    Google Scholar
     

  • Singh SP, Panigrahi MK, Patel A, Viswanathan L, Rath MM, Kar SK, et al. Comparison of Clinical, Biochemical, and Histopathologic Profiles between NAFLD in Asian-Indians and United States Adults. Eur J Hepato-gastroenterol. 2022;12(Suppl 1):S15-s18.

    Article 

    Google Scholar
     

  • Wang J, Sun H, Wang Y, An Y, Liu J, Wang G. Glucose metabolism status modifies the relationship between lipoprotein(a) and carotid plaques in individuals with fatty liver disease. Front Endocrinol. 2022;13:947914.

    Article 

    Google Scholar
     

  • Seko Y, Kawanaka M, Fujii H, Iwaki M, Hayashi H, Toyoda H, et al. Age-dependent effects of diabetes and obesity on liver-related events in non-alcoholic fatty liver disease: Subanalysis of CLIONE in Asia. J Gastroenterol Hepatol. 2022;37(12):2313–20.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sayiner M, Arshad T, Golabi P, Paik J, Farhat F, Younossi ZM. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population. Hep Intl. 2020;14(4):556–66.

    Article 

    Google Scholar
     

  • Blank V, Petroff D, Boehlig A, Heinze A, Karlas T, Berg T, et al. Clinical implications of hepatic structure and function evaluation based on vibration-controlled transient elastography and liver maximum function capacity test in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2022;34(6):686–92.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Bharath Kumar C, Goel A, Jaleel R, David D, Zachariah U, Ramachandran J, et al. Prevalence of Risk Factors for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Patients With Cryptogenic Cirrhosis. J Clin Exp Hepatol. 2022;12(2):492–502.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Boehlig A, Gerhardt F, Petroff D, van Boemmel F, Berg T, Blank V, et al. Prevalence of Pruritus and Association with Anxiety and Depression in Patients with Nonalcoholic Fatty Liver Disease. Biomedicines. 2022;10(2):451.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Antwi SO, Craver EC, Nartey YA, Sartorius K, Patel T. Metabolic risk factors for Hepatocellular Carcinoma in patients with nonalcoholic fatty liver disease: a prospective study. Cancers. 2022;14(24):6234.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Andrade TG, Xavier LCD, Souza FF, Araújo RC. Risk predictors of advanced hepatic fibrosis in patients with nonalcoholic fatty liver disease – a survey in a university hospital in Brazil. Arch Endocrinol Metabol. 2022;66(6):823–30.


    Google Scholar
     

  • Chen Y, Su H, Xue H, Wang T, Qian T, Liao C, et al. Correlation between serum total bile acid and nonalcoholic fatty liver disease: A cross-sectional study. Saudi J Gastroenterol. 2022;28(4):304–11.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kim H, Lee CJ, Ahn SH, Lee KS, Lee BK, Baik SJ, et al. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups. Dig Dis Sci. 2022;67(10):4919–28.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Truong E, Yeo YH, Cook-Wiens G, Muthiah M, Yang JD, Sundaram V, et al. Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017–2018. Hepatol Commun. 2022;6(9):2253–61.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wang Q, Zhu M, Li H, Chen P, Wang M, Gu L, et al. Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients. Diabetes Metabol Syndr Obes. 2022;15:1543–52.

    Article 

    Google Scholar
     

  • Trifan A, Rotaru A, Stafie R, Stratina E, Zenovia S, Nastasa R, et al. Clinical and laboratory characteristics of normal weight and obese individuals with non-alcoholic fatty liver disease. Diagnostics (Basel, Switzerland). 2022;12(4):801.

    CAS 
    PubMed 

    Google Scholar
     

  • Gray ME, Bae S, Ramachandran R, Baldwin N, VanWagner LB, Jacobs DR Jr, et al. Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Nutrients. 2022;14(4):854.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Younossi ZM, Stepanova M, Myers RP, Younossi I, Henry L. The potential role of fatigue in identifying patients with NASH and advanced Fibrosis who experience disease Progression. Clin Gastroenterol Hepatol. 2023;21(4):970-977.e971.

    Article 
    PubMed 

    Google Scholar
     

  • Sun T, Deng Y, Geng X, Fang Q, Li X, Chen L, et al. Plasma Alkylresorcinol Metabolite, a Biomarker for Whole-Grain intake, is inversely associated with risk of nonalcoholic fatty liver disease in a case-control study of Chinese adults. J Nutr. 2022;152(4):1052–8.

    Article 
    PubMed 

    Google Scholar
     

  • Saitta C, Caruso A, Maimone S, Filomia R, Cacciola I, Caccamo G, et al. Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity. Intern Emerg Med. 2022;17(6):1609–16.

    Article 
    PubMed 

    Google Scholar
     

  • Rinella ME, Satapathy SK, Brandman D, Smith C, Elwir S, Xia J, et al. Factors impacting survival in those transplanted for NASH Cirrhosis: data from the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023;21(2):445-455.e442.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Karamfilova V, Assyov Y, Nedeva I, Gateva A, Ivanova I, Cherkezov N, et al. Increased Serum Pentraxin 3 Is Associated with Prediabetes and Type 2 Diabetes in Obese Patients with Nonalcoholic Fatty Liver Disease. Metab Syndr Relat Disord. 2022;20(2):132–6.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Sripongpun P, Kim WR, Mannalithara A, Charu V, Vidovszky A, Asch S, et al. The steatosis-associated fibrosis estimator (SAFE) score: A tool to detect low-risk NAFLD in primary care. Hepatology. 2023;77(1):256–67.

    Article 
    PubMed 

    Google Scholar
     

  • Klaric KA, Parai JL, Kepron CA, Walker AE, Milroy CM. Postmortem survey of haemoglobin A1c, non-alcoholic steatohepatitis and liver fibrosis within a general population. J Clin Pathol. 2023;76(9):606–11.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ito T, Nguyen VH, Tanaka T, Park H, Yeh ML, Kawanaka M, et al. Poor Diagnostic Efficacy of Noninvasive tests for advanced Fibrosis in obese or younger than 60 Diabetic NAFLD patients. Clin Gastroenterol Hepatol. 2023;21(4):1013-1022.e1016.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Giammarino AM, Qiu H, Bulsara K, Khan S, Jiang Y, Da BL, et al. Community Socioeconomic Deprivation Predicts Nonalcoholic Steatohepatitis. Hepatol Commun. 2022;6(3):550–60.

    Article 
    PubMed 

    Google Scholar
     

  • Yu C, Wang M, Zheng S, Xia M, Yang H, Zhang D, et al. Comparing the Diagnostic Criteria of MAFLD and NAFLD in the Chinese Population: A Population-based Prospective Cohort Study. J Clin Transl Hepatol. 2022;10(1):6–16.

    Article 
    PubMed 

    Google Scholar
     

  • Jiang SX, Trasolini R, Heer M, Cox B, Galts C, Marquez V, et al. Non-alcoholic fatty liver disease (NAFLD) in Filipino North American patients: Results from a multi-ethnic cohort. Canadian liver journal. 2022;5(1):4–13.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Pariente A, Rosa I, Dharancy S, Hanslik B. Nonalcoholic fatty liver disease: opinions, population served, and management from a sample of French hepato(gastroentero)logists (PERSEPT study). Eur J Gastroenterol Hepatol. 2022;34(7):791–800.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kotronen A, Yki-Järvinen H, Männistö S, Saarikoski L, Korpi-Hyövälti E, Oksa H, et al. Non-alcoholic and alcoholic fatty liver disease – two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey. BMC Public Health. 2010;10:237.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Moctezuma-Velázquez P, Miranda-Zazueta G, Ortiz-Brizuela E, Garay-Mora JA, González-Lara MF, Tamez-Torres KM, et al. NAFLD determined by Dallas Steatosis Index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. Intern Emerg Med. 2022;17(5):1355–62.

    Article 
    PubMed 

    Google Scholar
     

  • Zeina AR, Kopelman Y, Mari A, Ahmad HS, Artul S, Khalaila AS, et al. Pulmonary embolism risk in hospitalized patients with nonalcoholic fatty liver disease: A case-control study. Medicine. 2022;101(45):e31710.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • van den Berg EH, Amini M, Schreuder TC, Dullaart RP, Faber KN, Alizadeh BZ, et al. Prevalence and determinants of non-alcoholic fatty liver disease in lifelines: A large Dutch population cohort. PLoS ONE. 2017;12(2):e0171502.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Zhao J, Fan H, Wang T, Yu B, Mao S, Wang X, et al. TyG index is positively associated with risk of CHD and coronary atherosclerosis severity among NAFLD patients. Cardiovasc Diabetol. 2022;21(1):123.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Masterton G, Hayes P. P31 Pattern and significance of biochemical abnormalities in referrals to a NAFLD clinic. 2010. https://doi.org/10.1136/gut.2010.223362.57. https://search.ebscohost.com/login.aspx?direct=true&db=edsbas&AN=edsbas.83BB32A5&lang=zh-cn&site=eds-live.

  • Deckmyn O, Poynard T, Bedossa P, Paradis V, Peta V, Pais R, et al. Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Biomedicines. 2022;10(3):699.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Reddy SK, Zhan M, Alexander HR, El-Kamary SS. Nonalcoholic fatty liver disease is associated with benign gastrointestinal disorders. World J Gastroenterol. 2013;19(45):8301–11.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li F, Ye J, Sun Y, Lin Y, Wu T, Shao C, et al. Distinct Dose-Dependent Association of Free Fatty Acids with Diabetes Development in Nonalcoholic Fatty Liver Disease Patients. Diabetes Metab J. 2021;45(3):417–29.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Alvarez CS, Graubard BI, Thistle JE, Petrick JL, McGlynn KA. Attributable Fractions of Nonalcoholic Fatty Liver Disease for Mortality in the United States: Results From the Third National Health and Nutrition Examination Survey With 27 Years of Follow-up. Hepatology. 2020;72(2):430–40.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Maurice JB, Goldin R, Hall A, Price JC, Sebastiani G, Morse CG, et al. Increased body mass index and type 2 diabetes are the main predictors of nonalcoholic fatty liver disease and advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection. Clin Infect Dis. 2021;73(7):e2184–93.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Huang J, Ou W, Wang M, Singh M, Liu Y, Liu S, et al. MAFLD Criteria Guide the Subtyping of Patients with Fatty Liver Disease. Risk Manag Healthcare Policy. 2021;14:491–501.

    Article 

    Google Scholar
     

  • Deng Y, Zhao Q, Gong R. Association Between Metabolic Associated Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study from NHANES 2017–2018. Diabetes Metabol Syndr Obes. 2021;14:1751–61.

    Article 

    Google Scholar
     

  • Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab. 2021;18(1):82.

    Article 
    CAS 

    Google Scholar
     

  • Lee GH, Phyo WW, Loo WM, Kwok R, Ahmed T, Shabbir A, et al. Validation of genetic variants associated with metabolic dysfunction-associated fatty liver disease in an ethnic Chinese population. World J Hepatol. 2020;12(12):1228–38.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li N, Xie G, Zhou B, Qu A, Meng H, Liu J, et al. Serum Adropin as a Potential Biomarker for Predicting the Development of Type 2 Diabetes Mellitus in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease. Front Physiol. 2021;12:696163.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tang LJ, Ma HL, Eslam M, Wong GL, Zhu PW, Chen SD, et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabol Clin Exp. 2022;128:154958.

    Article 
    CAS 

    Google Scholar
     

  • Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study. J Clin Endocrinol Metab. 2022;107(2):e745–55.

    Article 
    PubMed 

    Google Scholar
     

  • Rodriguez-Duque JC, Calleja JL, Iruzubieta P, Hernández-Conde M, Rivas-Rivas C, Vera MI, et al. Increased risk of MAFLD and Liver Fibrosis in inflammatory bowel disease independent of classic metabolic risk Factors. Clinical Gastroenterol Hepatol. 2023;21(2):406-414.e407.

    Article 
    CAS 

    Google Scholar
     

  • Park H, Yoon EL, Kim M, Lee J, Kim JH, Cho S, et al. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era. Hepatol Res. 2022;52(3):247–54.

    Article 
    PubMed 

    Google Scholar
     

  • Semmler G, Wernly S, Bachmayer S, Leitner I, Wernly B, Egger M, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality. J Clin Endocrinol Metab. 2021;106(9):2670–7.

    Article 
    PubMed 

    Google Scholar
     

  • Yang S, Cheng J, Zhang R, Sun H, Zhang H, Lyu S, et al. Metabolic dysfunction-associated fatty liver disease and liver fibrosis: Prevalence and associated factors in the middle-aged and older US population. Hepatol Res. 2022;52(2):176–86.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kim M, Yoon EL, Cho S, Lee CM, Kang BK, Park H, et al. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea. Liver Int. 2022;42(7):1536–44.

    Article 
    PubMed 

    Google Scholar
     

  • Alam S, Noor EASM, Chowdhury ZR, Alam M, Kabir J. Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh. World J Hepatol. 2013;5(5):281–7.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Salgado Alvarez GA, Pinto Galvez SM, Garcia Mora U, Cano Contreras AD, Durán Rosas C, Priego-Parra BA, et al. Higher cardiovascular risk scores and liver fibrosis risk estimated by biomarkers in patients with metabolic-dysfunction-associated fatty liver disease. World J Hepatol. 2022;14(8):1633–42.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Fukunaga S, Nakano D, Tsutsumi T, Kawaguchi T, Eslam M, Yoshinaga S, et al. Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis. Hepatol Res. 2022;52(8):699–711.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Guo Y, Yang J, Ma R, Zhang X, Guo H, He J, et al. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang. Nutrients. 2022;14(12):2361.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Drożdż K, Nabrdalik K, Kwiendacz H, Hendel M, Olejarz A, Tomasik A, et al. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach. Cardiovasc Diabetol. 2022;21(1):240.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Matsubayashi Y, Fujihara K, Yamada-Harada M, Mitsuma Y, Sato T, Yaguchi Y, et al. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex. Cardiovasc Diabetol. 2022;21(1):90.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Jamali R, Veisi S, Jamali A, Yaseri M. Relationship Between Cardiovascular Disease Risk Factors and Quality of Life in Patients with Metabolic-Associated Fatty Liver Disease. Hepat Mon. 2022;22(1):e124229.

  • Peng D, Yu Z, Wang M, Shi J, Sun L, Zhang Y, et al. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology. Front Endocrinol. 2022;13:935390.

    Article 

    Google Scholar
     

  • Lei F, Qin JJ, Song X, Liu YM, Chen MM, Sun T, et al. The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China. Front Endocrinol. 2022;13:1007171.

    Article 

    Google Scholar
     

  • Vítor Macedo S, Marta F, Sofia X, Pedro Boal C, Joana M, Carla M, et al. The New FibroScan-AST (FAST) Score: Enhancing Diabetes Mellitus Impact on Metabolic-Associated Fatty Liver Disease. GE Port J Gastroenterol. 2023;30(6):422–9.

  • Su W, Chen M, Xiao L, Du S, Xue L, Feng R, et al. Association of metabolic dysfunction-associated fatty liver disease, type 2 diabetes mellitus, and metabolic goal achievement with risk of chronic kidney disease. Front Public Health. 2022;10:1047794.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Seo JY, Cho EJ, Kim MJ, Kwak MS, Yang JI, Chung SJ, et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13(6):2953–60.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tang LJ, Li G, Eslam M, Zhu PW, Chen SD, Leung HH, et al. N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD. Hep Intl. 2023;17(1):190–201.

    Article 

    Google Scholar
     

  • Wang Y, Yu Y, Zhang H, Chen C, Wan H, Chen Y, et al. Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China. Front Endocrinol. 2022;13:968766.

    Article 

    Google Scholar
     

  • Yang J, Luo S, Li R, Ju J, Zhang Z, Shen J, et al. Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese. J Clin Endocrinol Metab. 2022;107(10):2874–82.

    Article 
    PubMed 

    Google Scholar
     

  • Zhang YC, Lyu ZY, Ma B, Li LM, Wang W, Sheng C, et al. A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population. Hep Intl. 2022;16(4):835–45.

    Article 
    CAS 

    Google Scholar
     

  • Chen X, Goh GB, Huang J, Wu Y, Wang M, Kumar R, et al. Validation of Non-invasive Fibrosis Scores for Predicting Advanced Fibrosis in Metabolic-associated Fatty Liver Disease. J Clin Transl Hepatol. 2022;10(4):589–94.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Tang X, Shi Y, Du J, Hu K, Zhou T, Chen L, et al. Clinical outcome of non-alcoholic fatty liver disease: an 11-year follow-up study. BMJ Open. 2022;12(6):e054891.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cai X, Wang M, Liu S, Yuan Y, Hu J, Zhu Q, et al. Establishment and validation of a nomogram that predicts the risk of type 2 diabetes in obese patients with non-alcoholic fatty liver disease: a longitudinal observational study. Am J Transl Res. 2022;14(7):4505–14.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Kim Y, Chang Y, Ryu S, Wild SH, Byrne CD. NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. Hepatology. 2022;76(6):1755–65.

    Article 
    PubMed 

    Google Scholar
     

  • Zhang H, Wang Y, Chen C, Wang B, Chen J, Tan X, et al. Non-alcoholic fatty liver disease, sleep behaviors, and incident type 2 diabetes. J Gastroenterol Hepatol. 2022;37(8):1633–40.

    Article 
    PubMed 

    Google Scholar
     

  • Arase Y, Suzuki F, Ikeda K, Kumada H, Tsuji H, Kobayashi T. Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease. J Gastroenterol. 2009;44(10):1064–70.

    Article 
    PubMed 

    Google Scholar
     

  • Chung GE, Cho EJ, Yoon JW, Yoo JJ, Chang Y, Cho Y, et al. Nonalcoholic fatty liver disease increases the risk of diabetes in young adults A nationwide population-based study in Korea. Metabol Clin Exp. 2021;123:154866.

    Article 
    CAS 

    Google Scholar
     

  • Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. N Engl J Med. 2021;385(17):1559–69.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wei Z, Ren Z, Hu S, Gao Y, Sun R, Lv S, et al. Development and validation of a simple risk model to predict major cancers for patients with nonalcoholic fatty liver disease. Cancer Med. 2020;9(3):1254–62.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Li WD, Fu KF, Li GM, Lian YS, Ren AM, Chen YJ, et al. Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus. World J Gastroenterol. 2015;21(32):9607–13.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Liu C, Wu Y, Duan W, Xu W. Cigarette Smoking Increases the Risk of Type 2 Diabetes Mellitus in Patients with Non-Alcoholic Fatty Liver Disease A Population-Based Cohort Study. Exp Clin Endocrinol Diabetes. 2022;130(12):793–800.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fukuda T, Hamaguchi M, Kojima T, Hashimoto Y, Ohbora A, Kato T, et al. The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int. 2016;36(2):275–83.

    Article 
    PubMed 

    Google Scholar
     

  • Nasr P, Fredrikson M, Ekstedt M, Kechagias S. The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease. Liver Int. 2020;40(5):1069–78.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Xia Y, Cao L, Zhang Q, Liu L, Zhang S, Meng G, et al. Adherence to a vegetable dietary pattern attenuates the risk of non-alcoholic fatty liver disease in incident type 2 diabetes: The TCLSIH cohort study. J Intern Med. 2022;291(4):469–80.

    Article 
    PubMed 

    Google Scholar
     

  • Lee CH, Han KD, Kim DH, Kwak MS. The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study. Front Endocrinol. 2021;12:638615.

    Article 

    Google Scholar
     

  • Bae JC, Han JM, Cho JH, Kwon H, Park SE, Park CY, et al. The persistence of fatty liver has a differential impact on the development of diabetes: The Kangbuk Samsung Health Study. Diabetes Res Clin Pract. 2018;135:1–6.

    Article 
    PubMed 

    Google Scholar
     

  • Tokita Y, Maejima Y, Shimomura K, Takenoshita S, Ishiyama N, Akuzawa M, et al. Non-alcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-aged Japanese Men and Women. Int Med (Tokyo, Japan). 2017;56(7):763–71.

    Article 

    Google Scholar
     

  • Zheng X, Cao C, He Y, Wang X, Wu J, Hu H. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching. Lipids Health Dis. 2021;20(1):59.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, et al. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004;20(1):45–9.

    Article 
    PubMed 

    Google Scholar
     

  • Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol. 2003;3:27.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Seko Y, Yano K, Takahashi A, Okishio S, Kataoka S, Okuda K, et al. FIB-4 Index and Diabetes Mellitus Are Associated with Chronic Kidney Disease in Japanese Patients with Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2019;21(1):171.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Friis-Liby I, Aldenborg F, Jerlstad P, Rundström K, Björnsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol. 2004;39(9):864–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Aliment Pharmacol Ther. 2005;21(4):407–13.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Lee J, Cho YK, Kang YM, Kim HS, Jung CH, Kim HK, et al. The Impact of NAFLD and Waist Circumference Changes on Diabetes Development in Prediabetes Subjects. Sci Rep. 2019;9(1):17258.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Barritt ASt, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2011;45(4):372–8.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, et al. Lean non-alcoholic fatty liver disease and development of diabetes: a cohort study. Eur J Endocrinol. 2019;181(2):185–92.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ming J, Xu S, Gao B, Liu G, Ji Y, Yang F, et al. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-year cohort study. Liver Int. 2015;35(11):2401–7.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Miyake T, Matsuura B, Furukawa S, Ishihara T, Yoshida O, Miyazaki M, et al. Fatty liver with metabolic disorder, such as metabolic dysfunction-associated fatty liver disease, indicates high risk for developing diabetes mellitus. J Diabetes Investig. 2022;13(7):1245–52.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cheng YM, Wang CC, Kao JH. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications. Hep Intl. 2023;17(2):350–6.

    Article 

    Google Scholar
     

  • IDF diabetes atlas. 9th ed. Brussels: International Diabetes Federation: International Diabetes Federation.; 2021 Available from: http://www.diabetesatlas.org.

  • Younossi Z, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672–82.

    Article 
    PubMed 

    Google Scholar
     

  • Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.

    Article 
    PubMed 

    Google Scholar
     

  • Jung HS, Chang Y, Kwon MJ, Sung E, Yun KE, Cho YK, et al. Smoking and the Risk of Non-Alcoholic Fatty Liver Disease: A Cohort Study. Am J Gastroenterol. 2019;114(3):453–63.

    Article 
    PubMed 

    Google Scholar
     

  • Meng G, Zhang B, Yu F, Li C, Zhang Q, Liu L, et al. Soft drinks consumption is associated with nonalcoholic fatty liver disease independent of metabolic syndrome in Chinese population. Eur J Nutr. 2018;57(6):2113–21.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • . Ageing World Health Organization2019 Available from: https://www.who.int/health-topics/ageing#tab=tab_1.

  • Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.

    Article 
    PubMed 

    Google Scholar
     

  • Sinclair A, Saeedi P, Kaundal A, Karuranga S, Malanda B, Williams R. Diabetes and global ageing among 65–99-year-old adults: Findings from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2020;162:108078.

    Article 
    PubMed 

    Google Scholar
     

  • Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020;9(4):1005.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754.

    Article 
    PubMed 

    Google Scholar
     

  • Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–73.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–52.

    Article 
    PubMed 

    Google Scholar
     

  • Yun Y, Kim HN, Lee EJ, Ryu S, Chang Y, Shin H, et al. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. PLoS ONE. 2019;14(3):e0213692.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.

    Article 
    PubMed 

    Google Scholar
     

  • Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology (Baltimore, MD). 2019;70(4):1457–69.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Steenblock C, Schwarz PEH, Ludwig B, Linkermann A, Zimmet P, Kulebyakin K, et al. COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol. 2021;9(11):786–98.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Li J, Tian A, Zhu H, Chen L, Wen J, Liu W, et al. Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19. Clin Gastroenterol Hepatol. 2022;20(7):1553-1560.e1578.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619-629.e617.

    Article 
    PubMed 

    Google Scholar
     

  • Ciardullo S, Perseghin G. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population. Liver Int. 2021;41(6):1290–3.

    Article 
    PubMed 

    Google Scholar
     

  • You may also like

    Leave a Comment

    1

    Today’s Diabetes News, your ultimate destination for up-to-date and insightful information on diabetes, health tips, and living a fulfilling life with diabetes. Our mission is to empower and support individuals with diabetes, their loved ones, and the wider community by providing reliable, relevant, and engaging content that fosters a healthier and happier life.

    Interesting Topics

    Most Viewed Articles

    Latest Articles

    Copyright MatchingDonors.com©️ 2024 All rights reserved.

    Are you sure want to unlock this post?
    Unlock left : 0
    Are you sure want to cancel subscription?